Rates of cognitive change in alzheimer disease: Observations across a decade of placebo-controlled clinical trials with donepezil

Alzheimer Disease and Associated Disorders

Volumn 23, Issue 4, 2009, Pages 357-364

  Jones, Roy W ^a   Schwam, Elias ^b   Wilkinson, David ^c   Waldemar, Gunhild ^d   Feldman, Howard H ^e   Zhang, Richard ^b   Albert, Kenneth ^b   Schindler, Rachel ^b  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b PFIZER INC   (United States)

^c MOORGREEN HOSPITAL   (United Kingdom)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer disease; Clinical trials; Cognition; Donepezil; Placebo

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIPARKINSON AGENT; CARDIOVASCULAR AGENT; DONEPEZIL; HYPOCHOLESTEROLEMIC AGENT; PLACEBO; PSYCHOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; EFFECT SIZE; FEMALE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; PARKINSONISM; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TRANSIENT ISCHEMIC ATTACK;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 70350288494     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31819cd4be     Document Type: Article

References (27)

1. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006;10:417-429.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd revised ed. Washington, DC: American Psychiatric Association;1987.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
4. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
5. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
6. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
7. Galasko DR, Gould RL, Abramson IS, et al. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Stat Med. 2000;19:1421-1432.
8. Mungas D, Reed BR. Application of item response theory for development of a global functioning measure of dementia with linear measurement properties. Stat Med. 2000;19: 1631-1644.
9. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996;7:293-303.
10. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021-1031.
11. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, doubleblind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998; 50:136-145.
12. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237-244.
13. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord. 2000;11:299-313.
14. Tune L, Tiseo PJ, Ieni J, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry. 2003;11:169-177.
15. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003;160:2003-2011.
16. Geldmacher DS, Perdomo C, Pratt R. Effect of donepezil treatment on visual attention/exploration tasks in patients with mild to moderately severe Alzheimer's disease: results of a pilot study [abstract]. Neurobiol Aging. 2000;21:S169.
17. Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004;19:624-633.
18. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590-1599.
19. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebocontrolled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481-488.
20. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001;57:2153]. Neurology. 2001;57:613-620.
21. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489-495.
22. Gold M. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007;68:430-438.
23. Sluimer JD, Vrenken H, Blankenstein MA, et al. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology. 2008;70(Pt 2):1836-1841.
24. Mungas D, Reed BR, Ellis WG, et al. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol. 2001;58: 1243-1247.
25. Wilson RS, Li Y, Aggarwal NT, et al. Education and the course of cognitive decline in Alzheimer disease. Neurology. 2004;63:1198-1202.
26. Barnes LL, Wilson RS, Li Y, et al. Racial differences in the progression of cognitive decline in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:959-967.
27. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2003:CD001190.